• We offer tailored partnerships to support and transform drug discovery.

    Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

  • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

    As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

  • Our OrganoReady program is made for you when you need optimized assays for investigational toxicology.

    We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon
EN

Screening of renal drug-transporter interactions in a 3D Human Proximal-Tubule-on-a-Chip

On-Demand Webinar

Better models for studying nephrotoxicity are desperately needed. Current in vivo or in vitro models do not always suffice. They can lack throughput, physiological relevance, and predictive power.

In the first webinar of this series, you learned how to develop an in vitro 3D model of fully polarized renal proximal tubular epithelial cells expressing active transporters that are necessary for your studies in the OrganoPlate®. In this webinar, you will learn how this model was further validated through drug-drug interaction studies focusing on two important efflux mechanisms in renal proximal tubules. Namely, the P-glycoprotein and the combined activities of Multidrug Resistance Proteins 2 and 4.

Imagine your nephrotoxicity studies bringing reliable, consistent, and physiologically relevant results quickly and by using human cell lines.

The OrganoPlate® platform is already successfully being used by the top 10 pharma as well as by hundreds of academic researchers worldwide.


In this webinar, you will learn:

  • How to choose a cell line and culture platform for reliable 3D in vitro nephrotoxicity studies
  • How to evaluate if your 3D in vitro model is physiologically relevant
  • How to study drug transport in 3D
  • How to easily qualify your in vitro 3D renal proximal tubule model with clinically relevant compounds

Register Here


What others have said about the OrganoPlate®

“With MIMETAS' OrganoPlate, we developed a 3D brain-on-a-chip model that made it easy to do high-throughput and high-content imaging to evaluate the acute toxicity of neurotoxins. OrganoPlate allowed the study of membrane-free vascular formation in a dynamic environment and further provided reliable and repeatable experiments with strong imagining capability.” — Dr. Yeoheung Yun, Associate Professor at North Carolina A&T State University

“Often you have to compromise: it’s either the throughput or it’s the complexity of the model. Getting both in the same platform…no other platforms can do that!” – Senior Scientist from top pharma


Speaker

Jelle Vriend, Toxicology Advisor at National Institute for Public Health and the Environment (RIVM)


Related publications



Cookies

May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy
Accept all
Accept selected
Decline all